<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">RADES, DIRK</style></author><author><style face="normal" font="default" size="100%">DELIKANLI, CANSU</style></author><author><style face="normal" font="default" size="100%">SCHILD, STEVEN E.</style></author><author><style face="normal" font="default" size="100%">KRISTIANSEN, CHARLOTTE</style></author><author><style face="normal" font="default" size="100%">TVILSTED, SOREN</style></author><author><style face="normal" font="default" size="100%">JANSSEN, STEFAN</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of Three Survival Scores in a Series of Patients ≥80 Years of Age Irradiated for Bone Metastases</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023-02-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">801-807</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.16221</style></doi><volume><style face="normal" font="default" size="100%">43</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Very elderly patients irradiated for bone metastases likely benefit from individualized treatments. A specific survival score was created for this group and compared to existing instruments. Patients and Methods: Ninety-six patients aged 80+ irradiated for bone metastases were retrospectively evaluated. Dose-fractionation regimen plus twelve characteristics were evaluated for survival. Results: In the Cox regression model, performance status and tumor type were significant and used for the score, which included three groups (5–7, 8–12, and 14 points) with 6-month survival rates of 15%, 52%, and 90%. Positive predictive values (PPVs) regarding death ≤6 months were 85% (new score), 100% (previous 65+ score), and 84% (previous score for any age). The new instrument and the 65+ score were also very accurate regarding survival. Since PPV regarding death was calculated from only four patients for the 65+ score, this PPV may be less conclusive than that for the new instrument. Conclusion: The new score appears useful for patients aged 80+ irradiated for bone metastases.</style></abstract></record></records></xml>